The Patent Finder

Autifony Therapeutics Limited

24 patents currently held · Updated Nov 21, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

4
Ending by 2030
Dec 2030
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Mar 15, 2027
    The maintenance fee for Compounds (US 9,133,175) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
  • 1 fee due May 24, 2027
    The maintenance fee for Hydantoin Derivatives as KV3 Inhibitors (US 9,193,704) comes due May 24, 2027. Unpaid by Nov 24, 2027, it lapses early.
  • 1 fee due Jun 22, 2027
    The maintenance fee for Imidazolidinedione Derivatives (US 9,216,967) comes due Jun 22, 2027. Unpaid by Dec 22, 2027, it lapses early.
  • 1 fee due Aug 11, 2027
    The maintenance fee for Compounds (US 10,555,945) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
  • 3 fees due Oct 2 to 28, 2027 · next Oct 2

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026
  • 1 term has ended since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,216,967Imidazolidinedione Derivatives
In force
 · High confidence
In forceHigh confidence
US 9,849,131Imidazolidinedione Derivatives
In force
 · High confidence
In forceHigh confidence
US 10,632,118Imidazolidinedione Derivatives
In force
 · High confidence
In forceHigh confidence
US 8,722,695Imidazolidinedione Derivatives
In force
 · High confidence
In forceHigh confidence
US 10,265,316Hydantoin Derivatives Useful as KV3 Inhibitors
In force
 · Low confidence
In forceLow confidence
US 11,197,859Hydantoin Derivatives Useful as KV3 Inhibitors
In force
 · Medium confidence
In forceMedium confidence
US 11,583,527Hydantoin Derivatives Useful as KV3 Inhibitors
In force
 · Medium confidence
In forceMedium confidence
US 9,193,704Hydantoin Derivatives as KV3 Inhibitors
In force
 · High confidence
In forceHigh confidence
US 9,346,790Hydantoin Derivatives Useful as KV3 Inhibitors
In force
 · High confidence
In forceHigh confidence
US 9,133,175Compounds
In force
 · USPTO record
In forceUSPTO record
10 of 24 patents shown.
Pro members see all 24.
Pro members: see all 24 patents
Also on record, not counted in the 24: 3 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 5 abandoned · 2 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited